The speed and severity of clinical progression after Alzheimer disease (AD) diagnosis varies and depends on multiple factors, most not well elucidated. We assessed whether body mass index (BMI) and 1-year weight change (WC) are associated with clinical progression in amnestic mild cognitive impairment (aMCI) and early-stage AD. Longitudinal data comprising 2268 aMCI and 1506 AD participants in the National Alzheimer's Coordinating Center's Uniform Data Set were used to examine nuances of clinical progression by BMI and WC, as well as potential variations in associations by age, sex, BMI (WC model), or apolipoprotein E genotype. In aMCI, high BMI (vs. moderate BMI) was associated with slower progression; weight loss (vs. no WC) was associated with faster progression. In AD, no significant differences were observed in clinical progression by BMI or WC. The association between BMI and clinical progression varied significantly by apolipoprotein E genotype in AD, and the association between WC and clinical progression varied significantly by sex and BMI in aMCI. Baseline BMI and 1-year WC in late life may serve as early prognostic indicators in aMCI and early-stage AD. If replicated, these results may help in counseling patients on anticipated clinical progression and suggest windows of opportunity for intervention.
A ge at diagnosis 1 and presence of comorbidities 2,3 are prognostic indicators of cognitive and functional decline and survival time in Alzheimer disease (AD). This study aimed to determine whether body mass index (BMI) and body weight change (WC) in late life are prognostic indicators of clinical progression in AD and in amnestic mild cognitive impairment (aMCI), a condition that often precedes AD.
Approximately 30% to 40% of patients with mild to moderate AD lose weight. 4, 5 Weight loss may begin 10 years before diagnosis, be more rapid 1 to 2 years preceding diagnosis, and be greater than expected for similarly aged individuals without AD. 6, 7 Low BMI and weight loss in later life have been associated with increased risk for AD. 8, 9 Reasons for weight loss in AD remain unclear and may differ depending on AD stage and severity. Proposed biological mechanisms for weight loss in AD include atrophy of the mesial temporal cortex, a region associated with eating behavior, or disruption of energy-regulating mechanisms. 10, 11 In addition, for a variety of social, environmental, medical, and health care reasons, healthy eating behaviors may be abandoned during progression and later stages of AD, resulting in weight loss and lower BMI. Thus, weight loss and low BMI could be useful predictors of clinical progression in AD and aMCI.
Few studies have examined whether BMI and WC are associated with clinical progression after aMCI or AD diagnosis. One study found that AD patients with Z4% weight loss over 1 year experienced a large drop in Mini-Mental State Examination (MMSE) score (Z3 points) over 6 months. 12 Another study found that there were faster declines in cognition over 1 year among MCI patients with lower baseline BMI and slower declines among those with higher BMI. 13 Focusing on individuals with incident AD, another study showed an 8% faster rate of cognitive decline for every 1-unit (kg/m 2 ) lower baseline BMI and a 40% faster rate of cognitive decline for every 1 unit decrease in BMI per year. 8 This study examined, in both aMCI and AD, whether: (1) clinical progression, defined as annual change in Clinical Dementia Rating sum of boxes (CDR-SB), is associated with BMI; (2) clinical progression is associated with 1-year WC; (3) these associations vary by age, sex, or apolipoprotein E (APOE) E4 status; and (4) the association between WC and clinical progression varies by BMI. Both BMI and WC were examined because BMI allows comparison with previous studies, whereas WC is a simple clinical marker of change in nutritional status. No studies to our knowledge have investigated these aims in both aMCI and AD. In addition, this study improves upon previous studies by defining the outcome measure using CDR-SB, a more sensitive measure of clinical progression. 14 
METHODS

Participants
Longitudinal data from the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS) were used to study participants with aMCI and early-stage AD at 32 US Alzheimer's Disease Centers (ADC). ADCs have collected demographic, clinical, diagnostic, and neuropsychological data on UDS participants with normal cognition, MCI, and dementia annually since 2005. Participants come from population-based samples, clinic samples, public recruitment efforts, participant referrals, and other ongoing studies. Because recruitment methods vary by ADC, UDS participants are best described as a clinical case series of patients from each ADC. Additional details about the UDS population are found elsewhere. 15, 16 Data collected between September 2005 and February 2012 were included in this study.
Amnestic MCI Sample
UDS participants diagnosed with aMCI had a cognitive complaint, abnormal cognition for their age (but no dementia), memory impairment, and essentially normal functional activities. 17 The participant's first UDS visit with an aMCI diagnosis (termed the index visit) was the starting point for including his/her data in the analysis (Supplemental Figure 1 , Supplemental Digital Content, http:// links.lww.com/WAD/A74). To ensure that the sample best represented aMCI, the MCI type most likely to progress to AD, 18 additional sample restrictions included: (1) global CDR score of 0.5; (2) CDR memory box score Z0.5; (3) MMSE score Z24; and (4) age at index visit Z55 years (Supplemental Figure 2 , Supplemental Digital Content, http://links.lww.com/WAD/A74). A younger age cutoff was used for aMCI than for AD because it often precedes AD. Our restrictions based on the CDR global score, CDR memory box score, and MMSE parallel those made for Alzheimer's Disease Neuroimaging Initiative participants. 19 
Early-stage AD Sample
Participants included in the AD sample were diagnosed with primary probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA). 20 The participant's first UDS visit with an AD diagnosis was the index visit (Supplemental Figure 1 , Supplemental Digital Content, http://links.lww.com/WAD/A74). To ensure our sample best represented early-stage AD, additional sample restrictions included: (1) global CDR score of 0.5 or 1.0; (2) MMSE between 20 and 26, inclusive; and (3) age at index visit 65 years or older (Supplemental Figure 2 , Supplemental Digital Content, http://links.lww.com/WAD/A74). Restrictions based on the CDR global score and MMSE parallel those made in Alzheimer's Disease Neuroimaging Initiative. 19 For our study, aMCI participants later diagnosed with AD were never included in the AD sample.
Outcome
The CDR, a well-accepted global measure of dementia severity based primarily on neurological examination and informant report, 21 was assigned to participants at each visit by a clinician. CDR-SB, 22 the outcome variable in all analyses, is a summary measure of the participants' scores for each of the 6 categories assessed: memory, orientation, judgment, community affairs, home and hobbies, and personal care (range, 0 to 18; higher score indicates greater impairment). The change in CDR-SB over time is best described as clinical progression as it assesses both cognitive and functional impairment.
Predictors
Participant height (inches) and body weight (pounds) were recorded at each visit. BMI (kg/m 2 ) was calculated from the height and weight at the index visit (iBMI) and categorized as low (< 20.0 kg/m 2 ), moderate (20.0 to <27.5 kg/m 2 ), or high (Z27.5 kg/m 2 ). The upper boundary chosen for moderate iBMI (27.5 kg/m 2 ) was based on mortality studies suggesting that a higher cutoff point might be more appropriate when defining normal BMI in older adults. 23, 24 One-year WC was calculated by dividing the difference between a participant's weight at the index visit and 1 year later by the index visit weight. The 1-year WC variable was then categorized as >4% weight loss, >4% weight gain, or no change (r4% weight gain or loss); the 4% WC cutoff point was based on published studies. 4, 25 BMI and WC were analyzed as categorical versus continuous variables because of past studies that have indicated a U-shaped relationship between BMI/WC and AD risk and cognitive decline 8, 26 and because these categories provide clinically relevant comparisons and have been associated with a variety of health outcomes previously. Results remained similar when iBMI and WC were included as continuous variables in post hoc analyses (data not shown).
Covariates
Potential confounders included age at index visit (y), sex, race/ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic other race, Hispanic of any race), years of education (r12 y, 13 to 16 y, Z17 y), Z1 comorbidity [reported history of diabetes, heart attack, heart failure, or cerebrovascular disease (transient ischemic attack or stroke)], history of hypercholesterolemia, history of hypertension, depression [Geriatric Depression Scale 27 score Z6 (range, 0 to 15)], and years since cognitive decline began (< 5 y, 5 to 9 y, or Z10 y between age at onset of cognitive decline and index visit). Age at onset of cognitive decline was assigned by clinicians after considering patient and informant report and other available clinical evidence. Presence versus absence of the APOE E4 allele, a recognized predictor of AD risk, was examined as a potential effect modifier. APOE genotyping is provided to NACC on a voluntary basis and was available for approximately 72% of our study sample.
Analyses
Descriptive statistics (mean and SD, or percentage) were calculated for the aMCI and AD samples. Linear mixed effects models were used to examine whether there were significant differences in the clinical progression rates by iBMI and 1-year WC.
All models were adjusted for clustering at the ADC and participant level and were run separately for aMCI and AD participants using SAS Proc MIXED. Time was represented in the longitudinal models as years from index visit. Each independent variable was considered timeinvariant. The participant's CDR-SB score was allowed to vary by visit, permitting an estimation of the average change in CDR-SB over time. All models allowed for a random slope and intercept, on the basis of indication of random effects from spaghetti plots. An exchangeable correlation structure was assumed for the random effects.
The unadjusted iBMI model contained iBMI, time, and interaction terms between iBMI and time. CDR-SB was included as the outcome variable in the iBMI analysis starting at the index visit. The unadjusted 1-year WC model contained 1-year WC, time, and interaction terms between 1-year WC and time. CDR-SB was included as the outcome variable in the analysis starting with the index + 1 visit, which ensured that the 1-year WC temporally preceded the measure of the annual clinical progression rate. The model coefficients for the interaction terms (ie, iBMIÂtime and WC Â time) provide the difference in clinical progression rates by iBMI and WC. A positive coefficient indicates a faster rate of clinical progression, and a negative coefficient indicates a slower rate of clinical progression, always in comparison with the moderate iBMI/no WC participants.
Multivariable models adjusted for iBMI (1-year WC model only), age at index visit, sex, race/ethnicity, education, comorbidities, years since cognitive decline began, and depression. These models estimated the average difference in clinical progression rates by iBMI or 1-year WC category, separately for aMCI and AD participants. Education, years since cognitive decline began, and depression were included as categorical measures in the model because the categories are more easily interpretable, and including continuous measures did not change the estimates in a meaningful way. A single variable for presence of Z1 comorbidity was used in the final model because so few participants had comorbidities and thus the model would not converge when comorbidities were included separately. Multivariable models were restricted to participants with nonmissing data. Unadjusted and adjusted models provided very similar results; therefore, the results section focuses on the multivariable analyses.
In each multivariable model, 3-way interactions between the main predictor (iBMI or 1-year WC), time, and the following covariates were tested (separately): above 75 years old at index visit, female sex, and APOE E4 status. Interactions between these variables were of interest because iBMI or WC may be stronger predictors of clinical progression for those who are older, male or female, or have Z1 APOE E4 allele. In addition, a 3-way interaction term between time, iBMI, and 1-year WC was evaluated. The estimated average clinical progression rate (CDR-SB change over time) was plotted only if the 3-way interaction term(s) significantly contributed to the multivariable model. An a level of 0.05 was used for all analyses.
Standard Protocol Approvals, Registrations, and Patient Consents
The Institutional Review Board at the University of Washington approved this study. Informed consent was obtained from all participants and informants at the individual ADCs.
RESULTS
Demographics
Our final sample consisted of 2268 aMCI participants and 1506 early-stage AD participants (Table 1 ). Mean follow-up time was 2.3 years (SD: 1.3 y). The mean age at index visit was 76.0 and 78.2 years for aMCI and AD participants, respectively. The majority of aMCI and AD participants were non-Hispanic white, and a greater percentage of the AD group had lower levels of education compared with the aMCI group. AD participants more frequently experienced cognitive decline Z5 years before the index visit compared with aMCI participants. The mean CDR-SB score at index visit was 1.3 and 4.6 for the aMCI and AD groups, respectively. In both diagnostic groups, approximately 5% had a low iBMI (< 20.0 kg/m 2 ) and 35% had high iBMI (Z27.5 kg/m 2 ). About 18% of aMCI participants and 21% of AD participants lost >4% of their index visit weight over 1 year, whereas 13% of aMCI participants and 18% of AD participants gained >4% of their index visit weight over 1 year. Among those with APOE data, the frequency of having Z1 APOE E4 allele was 45% and 62% for the aMCI and AD groups, respectively.
Adjusted iBMI Model, aMCI
Among aMCI participants, high iBMI (vs. moderate iBMI) was associated with an average 0.13-point higher baseline CDR-SB score and slower annual clinical progression rate (0.20 points slower per year) ( Table 2) . No significant differences in the baseline CDR-SB score or clinical progression rate were observed when comparing *Missing data (aMCI/AD): age (0.0%/0.0%), race/ethnicity (0.1%/ 0.3%), sex (0.0%/0.0%), education (0.2%/0.2%), comorbidities (0.0%/ 0.0%), hypercholesterolemia (0.0%/0.0%), hypertension (0.0%/0.0%), depression (1.5%/2.7%), years since cognitive decline began (7.5%/0.9%), CDR-SB (0.0%/0.0%), iBMI (0.0%/0.0%), 1-year WC (0.0%/0.0%), APOE (33.3%/21.2%).
wParticipants have 1 or more of the following comorbidities: diabetes, heart failure, cardiac arrest, or cerebrovascular disease (transient ischemic attack and/or stroke). AD indicates Alzheimer disease; aMCI, amnestic MCI; APOE, apolipoprotein E; CDR-SB, Clinical Dementia Rating Sum of Boxes; GDS, Geriatric Depression Scale; iBMI, body mass index at index visit; UDS, Uniform Data Set; WC, weight change. individuals in the low versus moderate iBMI groups. The association between iBMI and clinical progression did not vary by sex, age, or APOE E4 status (results not shown).
Adjusted iBMI Model, AD
Among AD participants, high iBMI (vs. moderate iBMI) was associated with an average 0.17-point higher baseline CDR-SB score but was not associated with clinical progression rate ( Table 2 ). Low iBMI was not associated with the baseline CDR-SB score or clinical progression rate. The association between iBMI and clinical progression did not differ by sex or age (results not shown); however, a slower clinical progression rate was observed for high iBMI participants without APOE E4 versus moderate iBMI participants without APOE E4 (P = 0.014) ( Fig. 1 ).
Adjusted 1-Year WC Model, aMCI
Among aMCI participants, weight loss and weight gain of >4% were not associated with baseline CDR-SB score, and >4% weight gain was not associated with clinical progression rate (Table 3 ). Weight loss of >4% (vs. no WC) was associated with a faster clinical progression rate (0.20 points faster per year) (P = 0.014). Among women, the clinical progression rate was faster for those experiencing >4% weight loss compared with those with no WC (P < 0.0001) ( Fig. 2A) . In moderate iBMI participants, clinical progression was faster among those experiencing >4% weight loss compared with those with no WC (P = 0.0001) (Fig. 2B) . In low iBMI participants, clinical progression was faster for those experiencing >4% weight gain compared with those with no WC (P = 0.020). In high iBMI participants, clinical progression was slower for those experiencing >4% weight gain compared with those with no WC (P = 0.049). Clinical progression rates did not differ by 1-year WC and APOE E4 status (data not shown).
Adjusted 1-Year WC Model, AD
Compared with AD participants experiencing no WC, baseline CDR-SB scores were 0.72 points higher for those with >4% weight loss and 0.52 points higher for those with >4% weight gain (Table 3) . No association was observed between WC and clinical progression rate. The association between WC and clinical progression did not vary by age, sex, APOE E4 status, or iBMI (data not shown).
DISCUSSION
In our study, high iBMI was associated with higher baseline impairment in aMCI and AD and slower clinical progression in aMCI. The magnitude and the direction of the estimated associations between high iBMI and clinical progression were similar in aMCI and AD, suggesting that high iBMI may also be associated with slower clinical progression in AD. In addition, the magnitude and direction of the estimated association between low iBMI and clinical progression were similar in aMCI and AD, suggesting a potential relationship between low iBMI and faster clinical progression.
It is interesting that high iBMI was associated with slower clinical progression for aMCI participants and for AD participants with no APOE E4 alleles. The UDS may capture a critical inflection point in the BMI-AD relationship, whereby higher average iBMI reflects the midlife BMI exposure and perhaps higher vascular risk for cognitive impairment, yet as aMCI or AD progresses, higher iBMI protects against progression. This inflection point dividing a risk state from a protective state has not been well described in the literature. The natural history of BMI in relation to aging and dementia has been illustrated in the Swedish birth cohort studies. 28, 29 It may also be that UDS participants with a high BMI are a subset of individuals not experiencing other life-threatening comorbidities associated with higher BMI, and thus represent more robust individuals who are less susceptible to cognitive decline.
Results for 1-year WC were inconsistent when comparing the aMCI and AD groups. A >4% one-year WC was associated with higher baseline CDR-SB scores among AD participants but not among aMCI participants. Although weight loss was associated with faster clinical progression in aMCI participants, this was not observed in AD participants. Weight gain was not significantly associated with clinical progression in either aMCI or AD participants; however, the magnitude of the estimate for the AD participants suggests a possible relationship between weight gain and faster clinical progression in AD. As few studies have examined whether a 1-year WC measure is associated with clinical progression in either aMCI or AD, these results are fairly novel and suggest that in aMCI, a >4% weight loss over 1 year could be predictive of faster clinical progression compared with those who maintain their weight.
Associations observed in our study were mostly limited to aMCI. One potential explanation is that weight loss is simply a statistical marker of neurodegeneration and associated cognitive decline during prodromal stages of AD (such as aMCI). Once AD is diagnosed, the difference in cognitive decline by degree of WC may be less discernable because, as a group, all are expected to experience similar levels of decline on average.
Our results complement the 3 studies previously described. 8, 12, 13 The primary findings from the Buchman study were replicated in our study. Those with weight loss experienced faster clinical progression and those with higher baseline BMI experienced slower clinical progression. Differences in results between the 3 studies and ours are likely due to selection of predictor and outcome measures and the populations within which the associations were evaluated. Cronk and colleagues used a continuous measure of BMI and found that MCI patients with lower BMI experienced slower annual declines using multiple measures of cognitive impairment (ie, MMSE, ADAS-cog, and a global composite measure), but not using CDR-SB. Soto and colleagues focused on AD patients and found faster cognitive decline over 6 months among those with 4% weight loss. Differences between their findings and ours could be related to their use of MMSE as the outcome, a 6month period to measure decline (vs. 1 y), and inclusion of individuals with later-stage AD (ie, an MMSE score as low as 10). We purposefully excluded those with later-stage AD from our sample to avoid bias due to possible "terminal decline" of cognition and weight experienced close to death.
The biological mechanisms behind weight loss and AD are not clear; however, several have been proposed. Changes in behaviors such as eating and exercise or genetic susceptibility (eg, APOE E4 genotype) may lead to weight loss. 30 A decline in BMI and in cognition may result from decreased energy metabolism due to declines in adipose and other tissues. Weight loss observed in AD patients may also result from changes in adipose tissue hormone levels, most of which have not been well characterized in aging or AD. Leptin, a hormone produced by adipose tissue and highly correlated with BMI, 31 may be dysregulated in aging and in AD as suggested by changes in the BMI trajectory and the data presented here. Increased leptin, due to obesity, negatively feeds back and suppresses appetite, in the healthy condition. Experimental data show that adipose-derived hormones, such as leptin and adiponectin, interact directly with hypothalamic nuclei and regulate energy expenditure and appetite. 32, 33 Leptin also appears to play important neuroprotective and developmental roles, such as shaping the hypothalamus in the earliest stages of development and in enhancing cognition. 34 In contrast, associations between low leptin levels and increased AD risk have led some scientists to suggest that leptin replacement therapy might reduce incident AD. 35, 36 Higher leptin levels in late life may indicate an adipose tissue mechanism whereby higher body weight in late life is protective against rapid cognitive decline. Hormonal regulation of energy metabolism needs further investigation but seems to be promising as a mechanism for changing body weight and cognitive decline in aMCI and/or AD.
The significant interaction between iBMI and WC depicts a dynamic state of BMI and WC in aMCI. We were interested in the possible interaction between iBMI and WC because it seemed likely that >4% weight loss in 1 year may be associated with faster clinical progression among those with low iBMI. Consistent with our expectations, we observed that the association between >4% weight loss and faster clinical progression may be primarily driven by participants with low or moderate iBMI who experienced a >4% weight loss. Similarly, the observed slower clinical progression among individuals with high iBMI may be driven primarily by the subgroup experiencing >4% weight gain. Although the mechanism for this association is unclear, our results suggest that individuals with higher BMI and/or who experience weight gain are protected from cognitive decline compared with those who have lower BMI and/or no weight gain. Future studies are needed to replicate our findings and examine the potential role of energyregulating mechanisms in changing body weight and clinical progression.
Recent research efforts have focused on sex-based differences in AD 37, 38 ; therefore, observed differences by sex were not unexpected. A few studies have demonstrated significantly different plasma leptin levels by sex, suggesting that sex-based interactions could be related to differences in energy-regulating hormones and metabolic changes associated with neurodegeneration. 39, 40 Among AD participants with no APOE E4 alleles, a slower clinical progression rate was observed among those with high iBMI (vs. moderate iBMI), and faster clinical progression was suggested for those with low iBMI (vs. moderate iBMI). Associations between risk factors and outcomes such as clinical progression have been observed only among those with no APOE E4 alleles in at least a few previous studies. 37 Our findings suggest that in the presence In aMCI: A, Significantly faster clinical progression among women with >4% weight loss versus women with no WC (P < 0.0001). There were no other significant differences by sex. B, Significantly faster clinical progression among moderate iBMI participants with >4% weight loss versus moderate iBMI participants with no WC (P = 0.0001), significantly faster clinical progression in low iBMI participants with >4% weight gain versus low iBMI participants with no WC (P = 0.020), and significantly slower clinical progression in high iBMI participants with >4% weight gain versus high iBMI participants with no WC (P = 0.049). There were no other significant differences by iBMI. AD indicates Alzheimer disease; aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; CDR-SB, Clinical Dementia Rating sum of boxes; iBMI, body mass index at the index visit; UDS, Uniform Data Set; WC, weight change.
of the APOE E4 allele, other risk factors may not be as strong predicting of clinical progression.
Our selected BMI and WC categories appear to be clinically meaningful and capable of discriminating differences in clinical progression in aMCI. We would not expect a substantial change in CDR-SB over time for individuals with MCI (the maximum expected CDR-SB score for an individual with MCI would be 4.0) and therefore our estimates are consistent with the expected change in CDR-SB among those with MCI. Regardless of the small expected annual change in CDR-SB in the aMCI group, our study found significant differences in annual CDR-SB change by BMI and WC category. Therefore, it appears that BMI, WC, and CDR-SB are clinically relevant and potential early indicators of AD.
Major strengths of this study are: (1) the large number of aMCI and AD participants who have been followed longitudinally allowing for the study of clinical progression;
(2) the standardized data collection protocols used across the ADCs; and (3) the availability of data on a number of potential clinical and demographic confounders. Weaknesses of this study include the: (1) potential lack of generalizability; (2) missing APOE genotype data for 28% of the sample; (3) lack of data on midlife BMI, which could be a significant confounder if long-term obesity contributes to greater impairment or a faster clinical progression; (4) small number of participants with low iBMI, limiting conclusions we can make about clinical progression among these individuals; and (5) relatively short follow-up time (average of 3 visits, up to 6 y of follow-up).
Our study suggests useful predictors of clinical progression rates following aMCI or AD diagnosis. Differences in iBMI and 1-year WC in late life may serve as early indicators of the underlying disease process in aMCI and early-stage AD, and thus may be useful and practical predictors of future clinical progression. If these findings are replicated, they may be useful in advising patients about expected clinical progression. This study adds to the literature because it uses a more sensitive measure of dementia and decline (CDR-SB) than measures used in past studies, and it is the first known study to assess whether WC is a predictor of clinical progression among individuals diagnosed with aMCI.
